Last reviewed · How we verify
Diltiazem HCl
Diltiazem HCl is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved. Also known as: calcium channel blocker, diltiazem, Bi-tildiem, Cardizem® CD (Biovail Pharmaceuticals, Inc.).
At a glance
| Generic name | Diltiazem HCl |
|---|---|
| Also known as | calcium channel blocker, diltiazem, Bi-tildiem, Cardizem® CD (Biovail Pharmaceuticals, Inc.), diltiazem immediate release oral tablet |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Edema
- Headache
- Dizziness
- Asthenia
- First degree AV block
- Bradycardia
- Flushing
- Nausea
- Rash
- AV Block First-DEGREE
- ECG ABNORMALITY
- Angina
Key clinical trials
- A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) (PHASE1)
- Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (PHASE1, PHASE2)
- Adenosine vs. Diltiazem (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (PHASE4)
- The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (PHASE4)
- Rate Control in Patients With Atrial Fibrillation (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diltiazem HCl CI brief — competitive landscape report
- Diltiazem HCl updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Diltiazem HCl
What is Diltiazem HCl?
Diltiazem HCl is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes Diltiazem HCl?
Diltiazem HCl is developed and marketed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
Is Diltiazem HCl also known as anything else?
Diltiazem HCl is also known as calcium channel blocker, diltiazem, Bi-tildiem, Cardizem® CD (Biovail Pharmaceuticals, Inc.), diltiazem immediate release oral tablet.
What development phase is Diltiazem HCl in?
Diltiazem HCl is FDA-approved (marketed).
What are the side effects of Diltiazem HCl?
Common side effects of Diltiazem HCl include Edema, Headache, Dizziness, Asthenia, First degree AV block, Bradycardia.
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Also known as: calcium channel blocker, diltiazem, Bi-tildiem, Cardizem® CD (Biovail Pharmaceuticals, Inc.), diltiazem immediate release oral tablet
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing